Pregabalin

普瑞巴林

Report date: 2026/05/25 20:02:40
NME

Base Information

Drug NamePregabalin
Drug Alias Name普加巴林Pregabalina普来噶巴林PregabalinumRegabatin +[12] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionVoltage-gated calcium channel alpha2/delta subunit 1 blockers
TargetsVoltage-gated calcium channel alpha2/delta subunit 1
Therapy Area/IndicationsSedationDiabetic peripheral neuropathyStress Disorders, Post-Traumatic +[62] 
Global Approved IndicationsAnxiety DisordersNeuralgia, PostherpeticNeuralgia +[7] 
Approved Indications in ChinaNeuralgia, Postherpetic
Original Approved Country/TerritoryEU
Original Approved Date2004/07/05
Country/TerritoryCzechiaBelgiumBosnia and Herzegovina +[63] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesUpjohn Us 2 LlcLatigo Biotherapeutics IncNational Institute of Geriatrics, Rheumatology and Rehabilitation +[16] 
Inactive CompaniesNevakar IncUnimed PharmaceuticalsViatris +[45] 
Active IndicationsStress Disorders, Post-TraumaticAnxiety DisordersPain Threshold +[17] 
Inactive IndicationsSedationDiabetic peripheral neuropathyAnxiety +[45] 

Other Information

ATC CodeN02BF02
Related LinksWikipediaDrugBankKEGG